stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) EV/FCF
As of 5 November 2026, QIAGEN N.V. (QGEN) trades at a EV/FCF of 25.8×. Over the past ten years it has ranged from 15.5× (September 2022) to 1,399× (October 2020); the current reading is higher than 27% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 25.4× | 16.08% |
| FY2024 | 21.8× | (41.16%) |
| FY2023 | 37.1× | 72.80% |
| FY2022 | 21.5× | (31.43%) |
| FY2021 | 31.3× | (63.77%) |
| FY2020 | 86.5× | (43.10%) |
| FY2019 | 152× | 273.90% |
| FY2018 | 40.6× | (16.28%) |
| FY2017 | 48.6× | 74.26% |
| FY2016 | 27.9× | (18.39%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 20.2× | (16.48%) |
| Mar 2026 | 24.2× | (4.41%) |
| Dec 2025 | 25.4× | 18.30% |
| Sep 2025 | 21.4× | (7.19%) |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| GH Guardant Health, Inc. compare | −84.7× |
| GRAL GRAIL, Inc. compare | −15.9× |
| ICLR ICON PLC compare | 22.6× |
| MEDP Medpace Holdings, Inc. compare | 25.7× |
| QGEN QIAGEN N.V. | 25.8× |
| RVTY Revvity Inc. compare | 32.6× |
| CRL Charles River Laboratories International, Inc. compare | 43.2× |
| BLLN BillionToOne, Inc. compare | 142× |
| RDNT RadNet, Inc. compare | 208× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement